



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Whole genome sequencing reveals genetic heterogeneity of G3P[8] rotaviruses circulating in Italy

This is the peer reviewed version of the following article:

Original

Whole genome sequencing reveals genetic heterogeneity of G3P[8] rotaviruses circulating in Italy / Medici, Maria Cristina; Tummolo, Fabio; Martella, Vito; Arcangeletti, Maria Cristina; DE CONTO, Flora; Chezzi, Carlo; Magri', Alessandro; Fehér, Enikő; Marton, Szilvia; Calderaro, Adriana; Bányai, Krisztián. - In: INFECTION GENETICS AND EVOLUTION. - ISSN 1567-1348. - 40:(2016), pp. 253-261. [10.1016/j.meegid.2016.03.013]

Availability:

This version is available at: 11381/2806144 since: 2021-11-12T14:29:45Z

Publisher:

Elsevier B.V.

Published

DOI:10.1016/j.meegid.2016.03.013

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

Dear Author,

Please, note that changes made to the HTML content will be added to the article before publication, but are not reflected in this PDF.

Note also that this file should not be used for submitting corrections.



Contents lists available at ScienceDirect

Infection, Genetics and Evolution

journal homepage: www.elsevier.com/locate/meegid

Q1 Whole genome sequencing reveals genetic heterogeneity of G3P[8] rotaviruses circulating in Italy

Q2 Maria Cristina Medici^{a,*}, Fabio Tummolo^a, Vito Martella^b, Maria Cristina Arcangeletti^a, Flora De Conto^a, Carlo Chezzi^a, Alessandro Magrì^a, Enikő Fehér^c, Szilvia Marton^c, Adriana Calderaro^a, Krisztián Bányai^c

^a Unit of Microbiology and Virology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

^b Department of Veterinary Medicine, University Aldo Moro of Bari, Valenzano, Italy

^c Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Budapest, Hungary

ARTICLE INFO

Article history:

Received 21 December 2015

Received in revised form 29 February 2016

Accepted 11 March 2016

Available online xxxx

Keywords:

Rotavirus

Italy

G3P[8]

Full genome analysis

Vaccines

ABSTRACT

After a sporadic detection in 1990s, G3P[8] rotaviruses emerged as a predominant genotype during recent years in many areas worldwide, including parts of Italy. The present study describes the molecular epidemiology and evolution of G3P[8] rotaviruses detected in Italian children with gastroenteritis during two survey periods (2004–2005 and 2008–2013). Whole genome of selected G3P[8] strains was determined and antigenic differences between these strains and rotavirus vaccine strains were analyzed. Among 819 (271 in 2004–2005 and 548 in 2008–2013) rotaviruses genotyped during the survey periods, the number of G3P[8] rotavirus markedly varied over the years (0/83 in 2004, 30/188 in 2005 and 0/96 in 2008, 6/88 in 2009, 4/97 in 2010, 0/83 in 2011, 9/82 in 2012, 56/102 cases in 2013). The genotypes of the 11 gene segments of 15 selected strains were assigned to G3-P[8]-I1-R1-C1-M1-A1-N1-T1-E1-H1; thus all strains belonged to the Wa genogroup. Phylogenetic analysis of the Italian G3P[8] strains showed a peculiar picture of segregation with a 2012 lineage for VP1–VP3, NSP1, NSP2, NSP4 and NSP5 genes and a 2013 lineage for VP6, NSP1 and NSP3 genes, with a 1.3–20.2% nucleotide difference from the oldest Italian G3P[8] strains. The genetic variability of the Italian G3P[8] observed in comparison with sequences of rotaviruses available in GenBank suggested a process of selection acting on a global scale, rather than the emergence of local strains, as several lineages were already circulating globally. Compared with the vaccine strains, the Italian G3P[8] rotaviruses segregated in different lineages (5–5.3% and 7.2–11.4% nucleotide differences in the VP7 and VP4, respectively) with some mismatches in the putative neutralizing epitopes of VP7 and VP4 antigens. The accumulation of point mutations and amino acid differences between vaccine strains and currently circulating rotaviruses might generate, over the years, vaccine-resistant variants.

© 2015 Published by Elsevier B.V.

1. Introduction

Group A rotavirus (RVA), family *Reoviridae*, is the major etiological agent of acute gastroenteritis in children during the early years of life (Estes and Greenberg, 2013).

The RVA genome is surrounded by a triple layered capsid, and is made up of 11 segments of double-stranded RNA (dsRNA), which encode six structural viral proteins (VP1–VP4, VP6 and VP7) and

five or six non-structural proteins (NSP1–NSP5 and sometimes NSP6) (Estes and Greenberg, 2013).

The traditional binary classification system for RVAs is based on the two outer capsid proteins VP7 (glycoprotein, G-genotype) and VP4 (protease sensitive protein, P-genotype). While at least 73 G/P genotype combinations have been described in humans (Matthijnsens et al., 2011), only a limited number of strains – G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], and to a lesser extent G12P[8] and G12P[6] – are most frequently associated with the RVA disease burden globally (Gentsch et al., 2005; Santos and Hoshino, 2005; Patel et al., 2011; Bányai et al., 2012; Cilla et al., 2013). A more complete RVA classification assigns genotypes to all 11 dsRNA segments, providing an opportunity to better characterize RVA strains and describe the molecular epidemiology of RVA infections in a greater detail (Matthijnsens

* Corresponding author at: Unit of Microbiology and Virology, Department of Clinical and Experimental Medicine, University of Parma, Viale Antonio Gramsci, 14, 43126 Parma, Italy.

E-mail address: maricristina.medici@unipr.it (M.C. Medici).

et al., 2008). Based on complete RVA genome sequence comparison, three human genotype constellations of the non-G, non-P genes have been described: Wa-like (genotype 1), DS-1-like (genotype 2), and AU-1-like (genotype 3).

G3 genotype presents the broadest host range and, consequently, the highest number of P type associations described for any other RV G type (Martella et al., 2003, 2010; Lee et al., 2003; Gentsch et al., 2005). Despite this high diversity, the majority of human G3 strains carries the P[8] VP4 genotype. G3P[8] strains have been found to circulate at low rates during the 1990s globally, except some Far East Asian countries. The re-emergence of G3P[8] RVAs in humans has been widely documented in the last decade (Ngo et al., 2009; Hull et al., 2011; Kirkwood et al., 2011; Mitui et al., 2011; Stupka et al., 2012; Gómez et al., 2014). The increased frequency of this strain in most of the reporting countries is supposed to be at expenses of the decrease of frequencies of G1P[8] and G9P[8] strains (Mitui et al., 2011; Stupka et al., 2012).

Two live-attenuated RVA vaccines, Rotarix (G1P[8]) and RotaTeq (G1-G4, P[8]), have been successfully introduced in many countries worldwide, including Italy. The parental RVA strains used to generate the vaccines were isolated more than 20 years ago and, at present, little is known about the relationship between currently circulating human RVAs and the vaccine strains.

The present study describes the molecular epidemiology of G3P[8] RVAs detected in Italian children with gastroenteritis during two survey periods (2004–2005 and 2008–2013). The whole genome of representative G3P[8] RVAs was determined. Also, the antigenic/genetic differences between G3P[8] RVAs circulating in Italy and vaccine RVA strains were investigated.

2. Material and methods

A total of 5729 children (range: 1 month–13 years and 6 months, median age: 4 years and 2 months) with gastroenteritis, as inpatients or outpatients at the Parma University Hospital, Northern Italy, was screened during 2004–2013 for RVA in stools by electron microscopy and latex agglutination (Orion Diagnostica). Molecular data were generated for the RVAs detected during 2004–2005 and 2008–2013. The stools resulted RVA positive in 2006 and 2007 were not available for genetic analyses. For RVA genotyping, viral RNA was extracted from stools using the RNaid Kit (BIO101), according to the manufacturer's instructions, and submitted to G/P typing protocols by multiplex semi-nested reverse transcription-PCR strategy (Medici et al., 2007; Ruggeri et al., 2011). Laboratory diagnosis for RVA infection was performed upon specific medical request. Patients' identity and subsequent medical information was adequately protected and remained anonymous during the study.

For full-genome sequencing of G3P[8] RVAs, reverse transcription was performed using AMV reverse transcriptase (Promega) with random hexamer tailed by a common PCR primer sequence (Djikeng et al., 2008). Polymerase chain reaction was carried out with Taq DNA polymerase (Thermo Scientific) applying the following thermal profile: initial denaturation (95 °C for 3 min) was followed by 40 cycles of amplification (95 °C for 30 s, 48 °C for 30 s, 72 °C for 2 min) and terminated at 72 °C for 8 min.

Approximately 30 to 40 ng cDNA obtained by the random RT-PCR were subjected to enzymatic fragmentation and adaptor ligation using the reagents supplied in the NEBNext Fast DNA Fragmentation & Library Prep Set for Ion Torrent kit (New England Biolabs) according to the manufacturer's instruction. Barcoded adaptors were retrieved from the Ion Xpress™ Barcode Adapters kit (Life Technologies). After size selection emulsion PCR was carried out on a OneTouch v2 instrument according to the manufacturer's protocol (Life Technologies). Templated beads were enriched on an Ion One Touch ES machine. The sequencing protocol recommended for the Ion PGM™ Sequencing 200 Kit v2 on a 316 v2 chip was strictly

followed. Raw sequence data were mapped onto reference G3P[8] RVA sequences obtained from the GenBank in the CLC Genomics Workbench version 7 (<http://www.clcbio.com/>). After visual inspection of the short-read sequence alignments, a single consensus sequence was finalized for each strain. The GenBank accession numbers of the G3P[8] Italian strains are KT988141–KT988305.

Multiple sequence alignments and phylogenetic tree constructions were performed with MEGA software (6.06) (Tamura et al., 2013), applying the maximum-likelihood method. Reliability of the phylogenetic trees was assessed by bootstrap re-sampling over 1000 replicates.

3. Results and discussion

After the introduction of RVA vaccines, surveillance for RVA has been intensified worldwide in order to gain pivotal information on the impact of vaccines on the epidemiology of RVA strains in the post-vaccine era (Bányai et al., 2012; Dóro et al., 2014).

In the prefecture of Parma (Emilia Romagna), Northern Italy, RVA vaccines were introduced officially in November 2006, with the approval of local health authorities. Although the RVA vaccines are strongly recommended by family pediatricians, they are not mandatory and therefore the vaccination coverage is not high. National and local data about vaccination coverage and data on the RVA prevalence after vaccine introduction are not available. A marked geographic heterogeneity in immunization practices has emerged in Italy as a consequence of the decentralization of the national health system. Only five (24%) regions (Lazio, Toscana, Basilicata, Piemonte, and Puglia) have included RVA vaccinations in their routine immunization schedules (Alfonsi et al., 2011). In our survey, the percentage of RVA infections in children with gastroenteritis showed a nearly three-fold reduction within a few years after the introduction/recommendation of RVA vaccines. In the pre-vaccine era the highest percentage of 36.7% was observed in 2006, while it decreased to 13.5% in 2013 (Table 1).

Among 819 genotyped RVA strains (271 in 2004–2005 and 548 in 2008–2013), significant annual changes of the G3P[8] relative proportion were observed. No G3P[8] RVA was detected in the years 2004, 2008 and 2011, whilst the G3P[8] detection rate was 16% in 2005, 6.8% in 2009, 4.2% in 2010, 11% in 2012 and 54.9% in 2013. Interestingly, G3P[8] became the predominant genotype during 2013, displacing the previous dominant G1P[8] genotype. The G1P[8] detection rate remained high even after the introduction of vaccines and decreased sharply from 96.4% in 2011 to 6.9% in 2013. Although, a limitation of the present study was the lack of a continue genotyping survey (no molecular data were generated from 2006 to 2007) the portrayed epidemiological picture can be considered representative of the RVAs circulating in the last decade in Parma. Our findings seem to reflect the trends described globally, confirming the increasing G3P[8] prevalence in the recent years (Hull et al., 2011; Kirkwood et al., 2011; Mitui et al., 2011; Stupka et al., 2012; Gómez et al., 2014). The increase of the number of G3P[8] cases in 2013 was not associated with a significant increase of the frequency of RVA detection. Likewise, changes in the rates of detection of G1P[8] cases over the years did not correlate with changes in RVA prevalence.

The percentage of RVA infections in children with gastroenteritis significantly decreased after the introduction of RVA vaccines, remaining under 16.4% after 2008. Continual monitoring is needed to understand the patterns and trends of the circulating RVA genotypes, chiefly for common G1P[8] and G3P[8] strains that showed significant yearly fluctuation in their prevalence.

Out of the 105 G3P[8] RVAs, 15 G3P[8] strains (at least two strains per year: two G3P[8] of 2005, four of 2009, two of 2010, two of 2012 and five of 2013) were randomly selected for full-genome sequencing. Upon genome sequence and phylogenetic analyses, all the 15 G3P[8] RVA strains were assigned to the gene constellation I1-R1-C1-M1-A1-

t1.1 **Table 1**
t1.2 Distribution of rotavirus G and P types detected in Italian children with gastroenteritis in 2004–2005 and 2008–2013.

G/P type	Year	2004	2005	2008	2009	2010	2011	2012	2013	Total
	No. of RVA detected (%)	83 (27.1)	188 (34.1)	96 (16.4)	88 (16)	97 (16)	83 (14)	82 (11.6)	102 (13.5)	819 (17.6)
	No. of children with gastroenteritis	306	551	586	551	606	597	705	758	4660
G1P[4]								2 (2.4)	7 (6.9)	9 (1.1)
G1P[8]		56 (67.5)	60 (31.9)	65 (67.7)	37 (42)	69 (71.1)	80 (96.4)	42 (51.2)	7 (6.9)	416 (50.8)
G2P[4]		3 (3.6)	5 (2.7)	1 (1)	10 (11.4)	1 (1)	1 (1.2)	5 (6.1)	7 (6.9)	33 (4)
G3P[4]						1 (1)				1 (0.1)
G3P[6]						1 (1)				1 (0.1)
G3P[8]			30 (16)		6 (6.8)	4 (4.2)		9 (11)	56 (54.9)	105 (12.8)
G4P[8]		13 (15.7)	2 (1)	2 (2)	9 (10.3)	19 (19.6)		9 (11)	18 (17.6)	72 (8.8)
G6P[9]								1 (1.2)		1 (0.1)
G8P[14]		1 (1.2)			1 (1.1)					2 (0.4)
G9P[8]		3 (3.6)	78 (41.5)	6 (6.3)	5 (5.8)				2 (2)	94 (11.4)
G10P[14]					1 (1.1)					1 (0.1)
G12P[6]									2 (2)	2 (0.4)
G12P[8]									2 (2)	2 (0.4)
Mixed G/P		7 (8.4)	13 (6.9)	22 (23)	19 (21.5)	2 (2.1)	2 (2.4)	14 (17.1)	1 (0.9)	80 (9.7)

t1.20 RVA: rotavirus group A. RVA prevalence in 2006: 36.7% (211/575). RVA prevalence in 2007: 22.1% (109/494).

199 N1-T1-E1-H1. This finding indicated that the G3P[8] RVAs belong to
200 genotype 1 (Wa-like).

201 Phylogenetic analysis showed that the 15 G3P[8] Italian strains
202 clustered within G3-Ia lineage (99.1–100% nucleotide identity) in the
203 VP7 tree and all the strains were grouped into the P[8]-III lineage
204 (97.1–100% nucleotide identity) in the VP4 tree, except a 2009 strain,
205 which segregated in the P[8]-IV lineage (Fig. 1).

206 When analyzing the backbone genes, the strains detected in 2005
207 and 2009–2010 clustered in a single common lineage and were more
208 closely related to contemporary G3P[8] detected globally. On the other
209 hand, the Italian G3P[8] strains detected in 2012–2013 showed a
210 peculiar pattern of segregation, with point mutations involving
211 different gene segments. Thus, the VP1, VP2, VP3, NSP1, NSP2,
212 NSP4 and NSP5 genes of the G3P[8] strains from 2012 segregated in
213 a lineage divergent from the oldest Italian strains (1.3–20.2% nucle-
214 otide difference). Likewise the 2013 G3P[8] RVAs grouped into a
215 separate lineage from the remaining Italian G3P[8] RVAs when
216 analyzing the VP6, NSP1, and NSP3 genes (4.6–18% nucleotide differ-
217 ence). Interestingly, the additional lineages of 2012 and 2013 RVAs
218 were closely related in some genes (VP1, VP3, VP6, and/or NSP4) to
219 the ancestral Wa strain detected in 1974. This clearly suggests that
220 the genome configuration of G3P[8] RVA has evolved over the years
221 due to mechanisms of genetic drift intermingled with intra-typic
222 reassortment, although, owing to the limited genome sequence
223 data still available in GenBank, it is impossible to determine the
224 exact temporal order of these events.

225 In the present study, for most gene segments different lineages
226 were found in the Italian G3P[8] strains, as observed in other large-
227 scale genomic studies investigating Wa-like RVAs (McDonald et al.,
228 2009; Roy et al., 2014; Zhang et al., 2014; da Silva et al., 2015;
229 Zeller et al., 2015). The genetic variability of the Italian G3P[8]
230 observed in comparison with sequences of rotaviruses available in
231 GenBank suggested a process of selection acting on a global scale,
232 rather than the emergence of local strains, as several lineages were
233 already circulating globally.

234 Finally, all the 15 Italian G3P[8] strains clustered in a branch different
235 from those of the VP7 gene of the pentavalent RotaTeq (5–5.3% nucleo-
236 tide difference and 2.8–3.4% amino acid difference) and in a lineage
237 different from those of the VP4 gene of the RotaTeq and Rotarix vaccines
238 (7.2–11.4% nucleotide difference and 6.8–9.7% amino acid difference).
239 Intra-genotypic differences (3 aa changes in VP7 and 4–9 aa changes
240 in VP4) were found within the putative neutralizing epitopes of both
241 antigens between the Italian G3P[8] strains and the RVA vaccines

(Figs. 2 and 3). Structural analyses are required to assess if amino acid
242 sequence changes in antigenic epitopes resulted in antigenic differences
243 between the vaccine and G3P[8] RVA strains currently circulating in
244 Italy. 245

246 Lineage replacement has been suggested as an important evolu-
247 tionary mechanism for RVAs to adapt to different immunological
248 environments and the observed changes in RVA strains and lineages
249 could be the result of natural fluctuations or the effect of vaccine-
250 driven evolution (McDonald et al., 2009; Dennis et al., 2014; Zhang
251 et al., 2014; Magagula et al., 2015; Zeller et al., 2015). Whether
252 protective immunity elicited by RVA vaccines may be affected not
253 only by differences in the VP7/VP4 types but also by different intra-
254 genotypic lineages is unclear. In this study we did not observed
255 changes in the VP7 and VP4 putative epitopes between the G3P[8]
256 RVAs circulating before and after vaccine introduction, even if they
257 differ in VP7 and VP4 antigens from vaccine strains. Whether, over
258 time, these differences may result in selection of strains able to
259 escape the RVA neutralizing-antibody pressure induced by vaccines
260 remains to be investigated (Zeller et al., 2012).

4. Conclusions 261

262 This study indicates that G3P[8] RVA strains tend to maintain
263 a stable Wa-like constellation, although the emergence of novel
264 lineages, evolving through accumulation of point mutations and
265 reassortment with older Wa-like RVAs, can affect in different ways
266 virus–host relationship. Genetic heterogeneity was observed in
267 G3P[8] RVAs in the VP6 gene, encoding the major capsid protein, in
268 2013, but not in 2012. This pattern was unique for the 2013 G3P[8]
269 RVAs and it was the only hallmark we could associate with the
270 spread of G3P[8] strains in 2013. This would imply mechanisms
271 that influence the efficacy of virus neutralization mediated by VP6-
272 specific antibodies (Burns et al., 1996), and confirm that besides
273 the surface proteins VP7 and VP4, also other viral proteins could be
274 involved in immune defense (Ward et al., 1993; Franco et al., 1997;
275 Bernstein and Ward, 2004; Corthésy et al., 2006). Further investiga-
276 tion of all relevant antigens is needed for a better understanding of
277 the immune defense against RVAs.

278 Whole genome characterization of RVA strains nicely complements
279 routine VP7 and VP4 genotyping assays and is pivotal to track the emer-
280 gence of novel RVA strains and to assess the long-term evolution of
281 common RVA strains.




Fig. 1. Phylogenetic dendrograms based on the nucleotide sequences of all 11 gene segments of rotaviruses. Italian G3P[8] rotaviruses detected in 2005 (■), in 2009 (▼), in 2010 (●), in 2012 (▲) and in 2013 (◆). In VP7 and VP4 vaccines strains are reported in bold. Trees were built with the maximum-likelihood method, and bootstrapped with 1000 repetitions. Bootstrap values are indicated at nodes of branches. Bar, number of nucleotide substitutions per site.




Fig. 1 (continued).




Fig. 1 (continued).

282 **Acknowledgments**

283 K. Bányai and A. Calderaro equally contributed to the co-ordination
284 of the study. This study was partly supported by project 'Epidemiologia

molecolare e studio dei meccanismi evolutivi di norovirus e rotavirus
285 umani' granted by the University of Parma, Italy (Fondi di Ateneo
286 2012). K. Bányai was supported by the Momentum program and the
287 Hungarian Scientific Research Program (OTKA, T100727).
288




Fig. 1 (continued).

	7-1a													7-1b					7-2											
	87	91	94	96	97	98	99	100	104	123	125	129	130	291	201	211	212	213	238	242	143	145	146	147	148	190	217	221	264	
RotaTeq-W178-9/G3P[5]	T	T	N	N	S	W	K	D	Q	D	A	V	D	K	Q	D	A	N	K	D	K	D	A	T	L	S	E	A	G	
PR799/2005	T	.	N	N
PR3602/2005	T	.	N	N
PR793/2009	T	.	N	N
PR781/2009	T	.	N	N
PR1470/2009	T	.	N	N
PR927/2009	T	.	N	N
PR204/2010	T	.	N	N
PR192/2010	T	.	N	N
PR348/2012	T	.	N	N
PR460/2012	T	.	N	N
PR640/2013	T	.	N	N
PR749/2013	T	.	N	N
PR837/2013	T	.	N	N
PR599/2013	T	.	N	N
PR1015/2013	T	.	N	N

Fig. 2. Alignment of the amino acid residues defining the neutralization domains (designated as 7-1a, 7-1b and 7-2) in VP7 of 13 Italian G3P[8] rotaviruses with those of the G3 strain of RotaTeq™ vaccine. Dots indicate conserved amino acids.

	VP8*															VP5*																						
	8-1					8-2					8-3					8-4			5-1					5-2	5-3	5-4	5-5											
	100	145	147	149	187	189	191	192	193	194	195	179	182	113	114	115	116	125	131	132	133	135	87	88	89	383	385	387	392	393	397	439	440	433	458	428	305	
Rotarix-A4ICB052A/G1P[8]	D	S	S	N	S	S	A	N	L	N	N	E	R	N	P	V	D	S	S	N	D	N	N	T	N	S	Y	S	A	W	N	L	R	E	N	S	L	
RotaTeq-W179-4/G6P[8]	D	S	S	N	S	N	A	N	L	N	D	E	R	N	P	V	D	N	R	N	R	D	D	N	T	N	R	H	S	A	W	N	L	R	E	N	S	L
PR799/2005	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR3602/2005	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR793/2009	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR781/2009	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR1470/2009	.	G	N	S	G	N	S	D	.	T	S	.	G	D	.	.	.	S	R	.	.	N	D	T	
PR927/2009	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR204/2010	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR192/2010	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR348/2012	.	G	.	.	.	N	.	.	.	D	G	N	R	.	.	D	D	
PR460/2012	.	G	.	.	.	N	.	.	.	D	G	N	R	.	.	D	D	
PR640/2013	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR749/2013	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR837/2013	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR599/2013	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	
PR1015/2013	.	G	.	.	.	N	G	.	.	D	.	.	.	N	R	.	.	D	D	

Fig. 3. Alignment of the amino acid residues defining the neutralization domains in VP8* (designated as 8-1, 8-2, 8-3, 8-4) and VP5* (designated as 5-1, 5-2, 5-3, 5-4, 5-5) epitopes of VP4 of 13 Italian G3P[8] rotaviruses with those of P[8] strains of Rotarix™ and RotaTeq™ vaccines. Dots indicate conserved amino acids.

References

Alfonsi, V., D'Ancona, F., Giambi, C., Nacca, G., Rota, M.C., 2011. The regional coordinators for infectious diseases and vaccinations. *Health Policy* 103, 176–183.

Bányai, K., Laszlo, B., Duque, J., Steele, A.D., Nelson, E.A., Gentsch, J.R., Parashar, U.D., 2012. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. *Vaccine* 30, A122–A130.

Bernstein, D.I., Ward, R.L., 2004. Rotaviruses. *Textbook of Pediatric Infectious Diseases*, fifth ed. vol. 2. Saunders, Philadelphia, PA, pp. 2110–2133.

Burns, J.W., Siadat-Pajouh, M., Krishnaney, A.A., Greenberg, H.B., 1996. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. *Science* 272, 104–107.

Cilla, G., Montes, M., Gomariz, M., Alkorta, M., Iturzaeta, A., Perez-Yarza, E.G., Perez-Trallero, E., 2013. Rotavirus genotypes in children in the Basque country (north of Spain): rapid and intense emergence of the G12[P8] genotype. *Epidemiol. Infect.* 141, 868–874.

Corthésy, B., Benureau, Y., Perrier, C., Fourgeux, C., Parez, N., Greenberg, H., Schwartz-Cornil, L., 2006. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. *J. Virol.* 80, 10692–10699.

Da Silva, M.F., Rose, T.L., Gómez, M.M., Carvalho-Costa, F.A., Fialho, A.M., Assis, R.M., Andrade Jda, S., Volotão Ede, M., Leite, J.P., 2015. G1P[8] species A rotavirus over 27 years—pre- and post-vaccination eras—in Brazil: full genomic constellation analysis and no evidence for selection pressure by Rotarix® vaccine. *Infect. Genet. Evol.* 30, 206–218.

Dennis, A.F., McDonald, S.M., Payne, D.C., Mijatovic-Rustempasic, S., Esona, M.D., Edwards, K.M., Chappell, J.D., Patton, J.T., 2014. Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: footprints of a globally transitioning genotype. *J. Virol.* 88, 3789–3801.

Djikeng, A., Halpin, R., Kuzmickas, R., Depasse, J., Feldblyum, J., Sengamalay, N., Afonso, C., Zhang, X., Anderson, N.G., Ghedin, E., Spiro, D.J., 2008. Viral genome sequencing by random priming methods. *BMC Genomics* 9, 5.

Dóro, R., László, B., Martella, V., Leshem, E., Gentsch, J., Parashar, U., Banyai, K., 2014. Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: is there evidence of strain selection from vaccine pressure? *Infect. Genet. Evol.* 28, 446–461.

Estes, M.K., Greenberg, H.B., 2013. Rotaviruses. In: Knipe, D.M., Howley, P.M. (Eds.), *Fields Virology*, sixth ed. Lippincott, Williams & Wilkins, Philadelphia, PA, pp. 1347–1401.

Franco, M.A., Tin, C., Greenberg, H.B., 1997. CD8? T cells can mediate almost complete short-term and partial long-term immunity to rotavirus in mice. *J. Virol.* 71, 4165–4170.

Gentsch, J.R., Laird, A.R., Bielfelt, B., Griffin, D.D., Banyai, K., Ramchandran, M., Jain, V., Cunliffe, N.A., Nakagomi, O., Kirkwood, C.D., Fischer, T.K., Parashar, U.D., Bresee, J.S., Jiang, B., Glass, R.I., 2005. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. *J. Infect. Dis.* 192, S146–S159.

Gómez, M.M., Carvalho-Costa, F.A., Volotão Ede, M., Rose, T.L., da Silva, M.F., Fialho, A.M., de Assis, R.M., Matthijssens, J., Leite, J.P., 2014. A decade of G3P[8] and G9P[8] rotaviruses in Brazil: epidemiology and evolutionary analyses. *Infect. Genet. Evol.* 28, 389–397.

Hull, J.J., Teel, E.N., Kerin, T.K., Freeman, M.M., Esona, M.D., Gentsch, J.R., Cortese, M.M., Parashar, U.D., Glass, R.I., Bowen, M.D., 2011. National Rotavirus Strain Surveillance System. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. *Pediatr. Infect. Dis. J.* 30, S42–S47.

Kirkwood, C.D., Boniface, K., Bishop, R.F., Barnes, G.L., 2011. Australian Rotavirus surveillance program: annual report, 2009/2010. *Commun. Dis. Intell.* 34, 427–434.

Lee, J.B., Youn, S.J., Nakagomi, T., Park, S.Y., Kim, T.J., Song, C.S., Jang, H.K., Kim, B.S., Nakagomi, O., 2003. Isolation, serologic and molecular characterization of the first G3 caprine rotavirus. *Arch. Virol.* 148, 643–657.

Magaglia, N.B., Esona, M.D., Nyaga, M.M., Stucker, K.M., Halpin, R.A., Stockwell, T.B., Seheri, M.L., Steele, A.D., Wentworth, D.E., Mphahlele, M.J., 2015. Whole genome analyses of G1P[8] rotavirus strains from vaccinated and non-vaccinated south African children presenting with diarrhea. *J. Med. Virol.* 87, 79–101.

- 350 Martella, V., Bányai, K., Matthijnsens, J., Buonavoglia, C., Ciarlet, M., 2010. Zoonotic
351 aspects of rotaviruses. *Vet. Microbiol.* 140, 246–255.
- 352 Martella, V., Ciarlet, M., Camarda, A., Pratelli, A., Tempesta, M., Greco, G., Cavalli, A., Elia, G.,
353 Decaro, N., Terio, V., Bozzo, G., Camero, M., Buonavoglia, C., 2003. Molecular charac-
354 terization of the VP4, VP6, VP7, and NSP4 genes of lapine rotaviruses identified in
355 Italy: emergence of a novel VP4 genotype. *Virology* 314, 358–370.
- 356 Matthijnsens, J., Ciarlet, M., McDonald, S.M., Attoui, H., Bányai, K., Brister, J.R., Buesa, J.,
357 Esona, M.D., Estes, M.K., Gentsch, J.R., Iturriza-Gomara, M., John, R., Kirkwood, C.D.,
358 Martella, V., Mertens, P.P., Nakagomi, O., Parreno, V., Rahman, M., Ruggeri, F.M., Saif,
359 L.J., Santos, N., Steyer, A., Taniguchi, K., Patton, J.T., Desselberger, U., Van Ranst, M.,
360 2011. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classi-
361 fication Working Group (RCWG). *Arch. Virol.* 156, 1397–1413.
- 362 Matthijnsens, J., Ciarlet, M., Rahman, M., Attoui, H., Bányai, K., Estes, M.K., Gentsch, J.R.,
363 Iturriza-Gomara, M., Kirkwood, C.D., Martella, V., Mertens, P.P., Nakagomi, O.,
364 Patton, J.T., Ruggeri, F.M., Saif, L.J., Santos, N., Steyer, A., Taniguchi, K., Desselberger, U.,
365 Van Ranst, M., 2008. Recommendations for the classification of group A rotaviruses
366 using all 11 genomic RNA segments. *Arch. Virol.* 153, 1621–1629.
- 367 McDonald, S.M., Matthijnsens, J., McAllen, J.K., Hine, E., Overton, L., Wang, S., Lemey, P.,
368 Zeller, M., Van Ranst, M., Spiro, D.J., Patton, J.T., 2009. Evolutionary dynamics of
369 human rotaviruses: balancing reassortment with preferred genome constellations.
370 *PLoS Pathog.* 5, e1000634.
- 371 Medici, M.C., Abelli, L.A., Martella, V., Martinelli, M., Lorusso, E., Buonavoglia, C., Dettori, G.,
372 Chezzi, C., 2007. Characterization of inter-genogroup reassortant rotavirus strains
373 detected in hospitalized children in Italy. *J. Med. Virol.* 79, 1406–1412.
- 374 Mitui, M.T., Chan, P.K., Nelson, E.A., Leung, T.F., Nishizono, A., Ahmed, K., 2011. Co-dominance
375 of G1 and emerging G3 rotaviruses in Hong Kong: a three-year surveillance in three
376 major hospitals. *J. Clin. Virol.* 50, 325–333.
- 377 Ngo, T.C., Nguyen, B.M., Dang, D.A., Nguyen, H.T., Nguyen, T.T., Tran, V.N., Vu, T.T., Ogino, M.,
378 Alam, M.M., Nakagomi, T., Nakagomi, O., Yamashiro, T., 2009. Molecular epidemiology of
379 rotavirus diarrhoea among children in Haiphong, Vietnam: the emergence of G3 rotavi-
380 rus. *Vaccine* 27, F75–F80.
- 381 Patel, M.M., Steele, D., Gentsch, J.R., Wecker, J., Glass, R.I., Parashar, U.D., 2011. Real-world
382 impact of rotavirus vaccination. *Pediatr. Infect. Dis. J.* 30, S1–S5.
- Roy, S., Esona, M.D., Kirkness, E.F., Akopov, A., McAllen, J.K., Wikswo, M.E., Cortese, M.M., 383
Payne, D.C., Parashar, U.D., Gentsch, J.R., Bowen, M.D., National Rotavirus Strain 384
Surveillance System; New Vaccine Surveillance Network, 2014. Comparative genomic 385
analysis of genogroup 1 (Wa-like) rotaviruses circulating in the USA, 2006–2009. *Infect.* 386
Genet. Evol. 28, 513–523.
- Ruggeri, F.M., Delogu, R., Petouchoff, T., Tcheremenskaia, O., De Petris, S., Fiore, L., 387
RotaNet-Italy Study Group, 2011. Molecular characterization of rotavirus strains 388
from children with diarrhea in Italy, 2007–2009. *J. Med. Virol.* 83, 1657–1668. 390
- Santos, N., Hoshino, Y., 2005. Global distribution of rotavirus serotypes/genotypes and its 391
implication for the development and implementation of an effective rotavirus vaccine. 392
Rev. Med. Virol. 15, 29–56. 393
- Stupka, J.A., Degiuseppe, J.I., Parra, G.I., the Argentinean National Rotavirus Surveillance 394
Network, 2012. Increased frequency of rotavirus G3P[8] and G12P[8] in Argentina 395
during 2008–2009: whole-genome characterization of emerging G12P[8] strains. 396
J. Clin. Virol. 54, 162–167. 397
- Tamura, K., Stecher, G., Peterson, D., Filipowski, A., Kumar, S., 2013. MEGA6: molecular 398
evolutionary genetics analysis version 6.0. *Mol. Biol. Evol.* 30, 2725–2729. 399
- Ward, R.L., McNeal, M.M., Sander, D.S., Greenberg, H.B., Bernstein, D.I., 1993. 400
Immunodominance of the VP4 neutralization protein of rotavirus in protective natu- 401
ral infections of young children. *J. Virol.* 67, 464–468. 402
- Zeller, M., Donato, C., Trovão, N.S., Cowley, D., Heylen, E., Donker, N.C., McAllen, J.K., 403
Akopov, A., Kirkness, E.F., Lemey, P., Van Ranst, M., Matthijnsens, J., Kirkwood, C.D., 404
2015. Genome-wide evolutionary analyses of G1P[8] strains isolated before and 405
after Rotavirus vaccine introduction. *Genome Biol. Evol.* 7, 2473–2483. 406
- Zeller, M., Patton, J.T., Heylen, E., De Coster, S., Ciarlet, M., Van Ranst, M., Matthijnsens, J., 407
2012. Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between 408
human rotaviruses circulating in Belgium and rotaviruses in rotarix and RotaTeq. *J. Clin.* 409
Microbiol. 50, 966–976. 410
- Zhang, S., McDonald, P.W., Thompson, T.A., Dennis, A.F., Akopov, A., Kirkness, E.F., Patton, 411
J.T., McDonald, S.M., 2014. Analysis of human rotaviruses from a single location over 412
an 18-year time span suggests that protein coadaptation influences gene constellations. 413
J. Virol. 88, 9842–9863. 414

415